Gapping up
In reaction to strong earnings/guidance: EVK +30.2%, SORL +24%, GOL +8.3%,SMTX +7.1%, DANG +6.9%, MOV +5.4%, BAMM +3.6%, CPHI +3.1%, AUPH +2.9%, SAIC+2.3%, CONN +1.2%
M&A news: CHTR +8.5% (Reuters report that company will soon acquire Bright House Networks), MRH +3.5% (to be acquired by Endurance Specialty Holdings (ENH) for $40.24 per share in cash and stock deal), JCI +1.7% (reached a definitive agreement for the sale of its Global WorkPlace Solutions business to CBRE Group (CBG) for $1.475 bln), .
Other news: OXGN +9% (Frigate Ventures disclosed 8.4% passive stake in 13G filing),BCRX +6.8% (awarded contract by BARDA for continued development of BCX4430 as potential treatment for diseases caused by RNA pathogens), ATRS +5% (announces that Ferring Pharmaceuticals has received FDA approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as ZOMACTON),DRYS +4.9% ( announces agreement to sell tanker fleet for an en-bloc sales price of $245 mln), GWPH +4% (initiates first Phase 3 pivotal trial for Epidiolex to treat Dravet Syndrome), AKAO +2.5% (to host webcast/teleconference providing an update on plazomicin tomorrow March 31 at 4:30pm ET), RDHL +1.2% (acquires Phase II Oral Small Molecule SK2 inhibitor From Apogee Biotech)
Analyst comments: CNDO +4.2% (upgraded to Buy from Hold at MLV & Co), HZNP +3.8% (upgraded to Overweight from Neutral at Piper Jaffray), IMGN +3.3% (upgraded to Buy from Hold at Cantor Fitzgerald), JCP +2.8% (target raised to $14 from $13 at Piper Jaffray),OVAS +1.5% (Science Magazine discusses the controversy around OVAS's AUGEMENT Fertility Treatment), PCLN +1.3% (upgraded to Buy from Hold at Stifel), MXPT +0.7% (initiated with an Outperform at Pacific Crest)
In reaction to strong earnings/guidance: EVK +30.2%, SORL +24%, GOL +8.3%,SMTX +7.1%, DANG +6.9%, MOV +5.4%, BAMM +3.6%, CPHI +3.1%, AUPH +2.9%, SAIC+2.3%, CONN +1.2%
M&A news: CHTR +8.5% (Reuters report that company will soon acquire Bright House Networks), MRH +3.5% (to be acquired by Endurance Specialty Holdings (ENH) for $40.24 per share in cash and stock deal), JCI +1.7% (reached a definitive agreement for the sale of its Global WorkPlace Solutions business to CBRE Group (CBG) for $1.475 bln), .
Other news: OXGN +9% (Frigate Ventures disclosed 8.4% passive stake in 13G filing),BCRX +6.8% (awarded contract by BARDA for continued development of BCX4430 as potential treatment for diseases caused by RNA pathogens), ATRS +5% (announces that Ferring Pharmaceuticals has received FDA approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as ZOMACTON),DRYS +4.9% ( announces agreement to sell tanker fleet for an en-bloc sales price of $245 mln), GWPH +4% (initiates first Phase 3 pivotal trial for Epidiolex to treat Dravet Syndrome), AKAO +2.5% (to host webcast/teleconference providing an update on plazomicin tomorrow March 31 at 4:30pm ET), RDHL +1.2% (acquires Phase II Oral Small Molecule SK2 inhibitor From Apogee Biotech)
Analyst comments: CNDO +4.2% (upgraded to Buy from Hold at MLV & Co), HZNP +3.8% (upgraded to Overweight from Neutral at Piper Jaffray), IMGN +3.3% (upgraded to Buy from Hold at Cantor Fitzgerald), JCP +2.8% (target raised to $14 from $13 at Piper Jaffray),OVAS +1.5% (Science Magazine discusses the controversy around OVAS's AUGEMENT Fertility Treatment), PCLN +1.3% (upgraded to Buy from Hold at Stifel), MXPT +0.7% (initiated with an Outperform at Pacific Crest)